Decision Resources Research Reports

Title	Published	Price
How Have Safety Concerns and New Warnings Affected the Anemia Market? By: Decision Resources The recombinant erythropoietin-stimulating agents (ESAs) revolutionized treatment of severe anemias, and the anemia market prospered—until accumulating data indicated that ESA treatment may be detrimental to patient survival. Black box warnings, tighter restrictions on ESA use \| more...	6/26/2008	$2,225.00
SPECIAL REPORT: 2008 Chartbook of International Pharmaceutical Prices By: Decision Resources In an increasingly globalized pharmaceutical market, drug pricing and reimbursement policies differ markedly among countries. Payers jealously guard their authority to set prices, and both they and government authorities exert growing pressure on manufacturers to \| more...	6/26/2008	$4,500.00
SPECIAL REPORT - Fueling the Drug Discovery Engine: Biotech Investment and Business Trends By: Decision Resources Promising new therapies and drug discovery approaches are within reach, but the pharmaceutical and biotechnology industries face unprecedented scientific, business, and regulatory challenges. Can the two industries develop and exploit a mutually beneficial synergy to \| more...	6/24/2008	$4,500.00
ORPHAN DISEASE SERIES - Cystic Fibrosis: Will New Agents Emerge as First-Line Therapies? By: Decision Resources The cystic fibrosis (CF) market is poised for significant change. The next generation of CF treatments all target the central mechanism responsible for organ damage in CF. These agents, as one thought leader states, “represent \| more...	6/20/2008	$4,500.00
Improving Return on Investment in Pharmaceutical Marketing By: Decision Resources Pharmaceutical marketing is in trouble—campaigns are not as effective as they should be, and costs have spiraled out of control. Marketing expenditures are the single largest corporate investment at most pharmaceutical companies and are running \| more...	6/17/2008	$2,225.00
Pharmaceutical Pricing and Reimbursement in France, 2008 By: Decision Resources France invests heavily in maintaining its outstanding universal healthcare system. However, drug prices in France—already among the lowest in Europe—are declining as a result of tough cost-containment measures targeted primarily at pharmaceutical companies. The government \| more...	6/11/2008	$2,225.00
ORPHAN DISEASE SERIES - Glaucoma: Can Orphan-Drug Status Offer an Entry into a Mature Market? By: Decision Resources The glaucoma market has not seen any new mechanisms for treatment since the launch of prostaglandin analogues in the mid 1990s. Despite the efficacy of existing agents, glaucoma treatment still exhibits a significant level of \| more...	6/11/2008	$4,500.00
The Landscape of Companion Diagnostics: Challenges, Opportunities, and Future Trends By: Decision Resources Diagnostics can be used to identify subgroups of patients who may or may not benefit from a companion drug, who may have adverse reactions to that drug, or who may require different doses of that \| more...	6/5/2008	$2,225.00
Product Life Spans: Trends in the Quality and Staying Power of New Products By: Decision Resources The commercial potential of products in development is vitally import to the pharmaceutical industry, which is now beset with productivity concerns, looming patent expiries, and declining growth rates. Many methods are used to produce sales \| more...	6/5/2008	$2,225.00
Emerging Diagnostic Technologies for Use in Psychiatric Indications By: Decision Resources The diagnosis of psychiatric diseases is an inexact science and a slow process for physicians. No laboratory tests are available to determine the exact disease—or treatment. New diagnostic technologies could offer earlier, more specific diagnosis \| more...	5/29/2008	$2,225.00
Blood Biomarkers and Beyond: Biomarker and Diagnostic Opportunities in Cardiovascular Disease By: Decision Resources Demographic and cost data provide clear reasons for pharmaceutical industry investment in CVD biomarkers and diagnostics. CVDs are highly prevalent and potentially lethal diseases with high treatment costs; biomarkers offer the potential to decrease these \| more...	5/28/2008	$2,225.00
Pharmaceutical Pricing and Reimbursement in Japan, 2008 By: Decision Resources The pharmaceutical industry faces challenging times in the Japanese market. The government has expressed its desire to reward the development of innovative medicines and has promised more-generous price premiums for innovative drugs. At the same \| more...	5/27/2008	$2,225.00
Amyotrophic Lateral Sclerosis: Strategies for Drug Developers By: Decision Resources Only one drug is approved for the treatment of ALS, and its only benefit is a modest increase in survival time. Commercial development in this disease has been minimal, with companies being dissuaded by the \| more...	5/19/2008	$4,500.00
Pharmaceutical Pricing and Reimbursement in Italy, 2008 By: Decision Resources Italy was the only major pharmaceutical market to experience a decline in 2007.The country’s leading pharmaceutical-industry association has warned the Italian government that without a radical change in Italian pharmaceutical policy, the industry’s competitiveness in \| more...	5/7/2008	$2,225.00
Obsessive-Compulsive Disorder: Strategies to Maximize Opportunities in a Small Market By: Decision Resources Although the obsessive-compulsive disorder (OCD) market is small and OCD diagnosis rates are low, this market is characterized by substantial unmet need and commercial opportunity. Companies looking to expand their agents into this market need \| more...	5/7/2008	$2,225.00
Asia: Threat or Opportunity? By: Decision Resources Asian economic might is growing, and the Asian pharmaceutical markets and industry are growing along with it. Western pharmaceutical companies have become very interested in entering Asian markets and taking advantage of the opportunities they \| more...	5/5/2008	$2,225.00
Pharmaceutical Pricing, Reimbursement, and Prescribing News in the First Quarter of 2008 By: Decision Resources Spending on prescription drugs continues to grow in worldwide markets—but not as fast as other healthcare expenditures. Consequently, the pharmaceutical industry’s relatively modest share of total healthcare costs— less than 15% in most mature markets—is \| more...	4/30/2008	$2,225.00
Biologics Pipelines: Who Has the Next Promising Recombinant Proteins? By: Decision Resources Introduction Therapeutic recombinant protein development has added a broad range of new products to the pharmaceutical armamentarium and led to a burgeoning biotechnology industry that is growing much faster than the small molecule- \| more...	4/22/2008	$2,225.00
Targeting Kinases for Drug Discovery By: Decision Resources Introduction Protein kinases—intracellular enzymes that modulate cellular functions—play a pivotal role in the signal transduction processes that regulate many key biological processes. Abnormalities in these signal transduction pathways are implicated in the \| more...	4/17/2008	$2,225.00
Harnessing Biomarker Research in Academic Institutions for Use in Industry By: Decision Resources Introduction Academic research institutions are a rich source of technology for commercial biomarker development. Some of today’s most dynamic biomarker discoveries originated from academic-industrial relationships, resulting in millions of dollars for universities and billions \| more...	4/3/2008	$2,225.00
Diabetic Nephropathy By: Decision Resources A therapy that is more effective than irbesartan in inducing regression from microalbuminuria to normoalbuminuria for the treatment of diabetic nephropathy. Using Target Product Profiles in Your Market Strategy Our \| more...	3/30/2008	$7,500.00
Benign Prostatic Hyperplasia By: Decision Resources A drug with lower incidence of sexual side effects than tamsulosin for the treatment of benign prostatic hyperplasia. Using Target Product Profiles in Your Market Strategy Our Target Product \| more...	3/30/2008	$7,500.00
Mild Cognitive Impairment By: Decision Resources A therapy that improves ADAS-cog score from baseline at 12 months for the treatment of mild cognitive impairment. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles \| more...	3/30/2008	$7,500.00
Major Depression By: Decision Resources A therapy that can prevent recurrence of major depressive disorder in a greater percentage of patients than venlafaxine XR does at one year. Using Target Product Profiles in Your Market Strategy \| more...	3/30/2008	$7,500.00
Insomnia By: Decision Resources A hypnotic that is free of next-day residual effects for the treatment of insomnia. Using Target Product Profiles in Your Market Strategy Our Target Product Profiles qualitatively predict the market \| more...	3/30/2008	$7,500.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2008, All Rights Reserved, MarketResearch.com
7/23/2008 - 1